Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

BMA calls for mass child vaccinations for hepatitis B virus (HBV)

The British Medical Association (BMA) has today called for all children in the UK to be immunised against a potentially fatal liver disease caused by the hepatitis B virus (HBV).

9 May 2005

Major Chinese breakthrough for pSivida - patent granted

This first patent grant in China is important as China has the highest incidence of primary liver cancer in the world with 345,844 cases in 2002 and is a logical target market for BrachySil. The potential lower cost of the Chinese registration pathway and the vast need of BrachySil like products make China an important commercial target.

9 May 2005

Small number of genes can predict response to chronic hepatitis C therapy

For the first time, physicians at University Health Network and University of Toronto have identified a small subset of genes that can predict whether a patient with chronic Hepatitis C will be able to respond to current treatments.

2 May 2005

Asians and Pacific Islanders have the highest levels of iron in their blood

UAB and international scientists studying iron-overload disorders have made the unexpected discovery that Asians and Pacific Islanders have the highest levels of iron in their blood of all racial/ethnic groups who were screened.

27 Apr 2005

High levels of immunosuppressant may lead to tumor recurrence

A new study on the incidence of liver cancer after transplant found that high levels of the immunosuppressant cyclosporine favored tumor recurrence and identified blood levels of the drug that should not be exceeded. Lower levels of cyclosporine levels did not affect rejection rates.

22 Apr 2005

pSivida moves to full development programme of pancreatic cancer product

pSivida Limited has announced that it has initiated a full development programme of its proprietary BrachySil product in a second key cancer indication. Development has commenced to evaluate the efficacy and safety of this novel brachytherapy product in pancreatic cancer, with the clinical programme scheduled to commence before the end of 2005.

7 Apr 2005

Chemoembolization, first-line treatment for liver cancer

New research by Jeff Geschwind, M.D., director of interventional radiology and associate professor at Johns Hopkins University School of Medicine, has shown that liver cancer patients, most of whom have inoperable tumours, could benefit from chemoembolization, a nonsurgical treatment option that delivers a high-dose of chemotherapy to the tumour while decreasing blood flow through the arteries feeding the tumour, known as embolization.

4 Apr 2005

Construction will enable pSivida to increase BrachySil production

Global nanotechnology company pSivida Limited has announced that it's UK manufacturing partner, Atomising Systems Ltd ("ASL"), has reached a key milestone in the manufacture of BrachySil, its lead product, by completing construction of a state of the art dedicated cleanroom facility to GMP specifications at its Sheffield plant in the United Kingdom. ASL is a world leader in high temperature atomising technology.

30 Mar 2005

New drug to treat chronic hepatitis B

The U.S. Food and Drug Administration (FDA) has given approval for a new drug to treat the potentially life-threatening disease Chronic hepatitis B.

30 Mar 2005

Hope of new treatments for liver damage

There is currently no cure for liver cirrhosis and a patient's only hope of survival is to receive a liver transplant.

28 Mar 2005

Strawberries destroy cancer cells

Researchers specializing in the health benefits of plant compounds have shown that quercetin, a phytonutrient found in abundance in strawberries and other fruits, can induce programmed self-destruction of human cancer cells.

23 Mar 2005

New study to evaluate Pegasys and Copegus to treat hepatitis C in liver transplant patients

Roche has initiated a new study to evaluate treatment strategies to reduce post-transplant recurrence of hepatitis C infection with the most prescribed hepatitis C treatment combination in the U.S., Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP).

21 Mar 2005

Antiretroviral therapy may prevent some cancers in people with HIV

In people infected with human immunodeficiency virus (HIV), highly active antiretroviral therapy (HAART) may prevent most excess cases of Kaposi sarcoma and non-Hodgkin lymphoma, according to a new study in the March 16 issue of the Journal of the National Cancer Institute.

15 Mar 2005

New hepatitis drug wins approval by FDA

An experimental hepatitis B drug has earned the praise of US health experts for its effectiveness and has been recommended by the US Food and Drug Administration (FDA) advisory panel to treat the liver disease in adults.

14 Mar 2005

Diabetic patients run three times the risk of developing liver cancer

The researchers trawled a surveillance database used for patients in receipt of Medicare funding for health care, to identify patients aged 65 and older, who had been diagnosed with liver cancer.

7 Mar 2005

Association noted between certain non-lver cancers and hepatitis C

People infected with the hepatitis C virus (HCV) have a higher risk of developing non-Hodgkin's lymphoma and multiple myeloma, according to a recent study of the Swedish population.

22 Feb 2005

Scientists have replicated hepatitis C virus (HCV) in the laboratory

For the first time, scientists have replicated hepatitis C virus (HCV) in the laboratory. The ability to replicate HCV in cell culture will allow researchers to better study the life cycle and biology of this virus and to test potential antiviral compounds, which may lead to new therapies for the liver disease that results from infection with HCV.

22 Feb 2005

2.5 million euros helps fight liver cancer

The overall project will concentrate on three areas where Europe is in a relatively favourable position compared with the US - human tissue resources, ribonucleic acid (RNA) technology, and structural proteomics. However, the initial focus will be on the development of genomics targets in hepatocellular carcinoma (HCC) or liver cancer as it is one of the leading causes of cancer death worldwide and has a very poor prognosis.

22 Feb 2005

Studies reveal methods viruses use to sidestep immune system

A series of studies by researchers at UT Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart a host's immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the common cold.

17 Feb 2005

Nonsurgical microspheres an option for liver cancer patients

A study in February’s Journal of Vascular and Interventional Radiology found that patients undergoing liver cancer treatment with Theraspheres?, radioactive microspheres containing Yittrium-90, can tolerate a 150 Gy single dose or 268 Gy repeated dose without risk of radiation-induced liver disease.

17 Feb 2005